Abstract
To better understand the factors underlying the continued incidence of clinical episodes of falciparum malaria in E-2020 countries targeting elimination, we have characterised Plasmodium falciparum disease transmission dynamics after a clonal outbreak on the northwest coast of Ecuador over a period of two years. We apply a novel, high-resolution genotyping method, the “varcode” based on a single PCR to fingerprint the DBLα region of the 40-60 members of the variant surface antigen-encoding var multigene family. Var genes are highly polymorphic within and between genomes, with var repertoires rapidly evolving by outcrossing during the obligatory sexual phase of P. falciparum in the mosquito. The continued incidence of clinical malaria after the outbreak in Ecuador provided a unique opportunity to use varcodes to document parasite microevolution and explore signatures of local disease transmission on the time scale of months to two years post-outbreak. We identified nine genetic varcodes circulating locally with spatiotemporal parasite genetic relatedness networks revealing that diversification of the clonal outbreak parasites by sexual recombination was associated with increased incidence of clinical episodes of malaria. Whether this was due to chance, immune selection or sexual recombination per se is discussed. Comparative analyses to other South American parasite populations where P. falciparum transmission remains endemic elucidated the possible origins of Ecuadorian varcodes. This analysis demonstrated that the majority of clinical cases were due to local transmission and not importation. Nonetheless, some of the varcodes that were unrelated to the outbreak varcode were found to be genetically related to other South American parasites. Our findings demonstrate the utility of the varcode as a high-resolution surveillance tool to spatiotemporally track disease outbreaks using variant surface antigen genes and resolve signatures of recombination in an E-2020 setting nearing elimination.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was financially supported by the Pontificia Universidad Católica del Ecuador (grant numbers: L13058, L13248, M13416, N13416, O13087[QINV0084] to F.E.S), the Fogarty International Center at the National Institutes of Health [Program on the Ecology and Evolution of Infectious Diseases (EEID), Grant number: R01-TW009670 to K.P.D.], and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health (grant number: R01-AI084156 to K.P.D.). S.R-P. was supported by a Melbourne International Engagement Award from the University of Melbourne and gratefully acknowledges the J.D. Smyth Travel Award from the Australian Society for Parasitology that enabled her to travel to Ecuador to establish this collaborative project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The P. falciparum isolates collected from individuals of all ages presenting with uncomplicated malaria cases were obtained from the malaria surveillance protocol approved by the Ethical Review Committee of Pontificia Universidad Católica del Ecuador. Ethical approval for this study was obtained from Pontificia Universidad Católica del Ecuador (Quito, Ecuador) and University of Melbourne (Melbourne, Australia). Written informed consent was provided by study participants and/or their legal guardians.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The cleaned DBLα sequences generated in this study from Ecuadorian P. falciparum isolates have been submitted to the DDBJ/ENA/GenBank (BioProject Number: PRJNA642683). The python code for the DBLαCleaner pipeline is available on GitHub at https://github.com/Unimelb-Day-Lab/DBLaCleaner. The python code for the clusterDBLalpha pipeline is available on GitHub at https://github.com/Unimelb-Day-Lab/DBLalpha. The python code for the classifyDBLalpha pipeline is available on GitHub at https://github.com/Unimelb-Day-Lab/classifyDBLalpha. All other deidentified data and analysis code are available on the open-source GitHub repository at https://github.com/shaziaruybal/varcode-ecuador.
